Imipenem is a semisynthetic thienamycin. Imipenem is one of the broad-spectrum antibiotics that has a bactericidal action against multiple gram-negative, gram-positive, aerobic, and anaerobic bacteria by binding to penicillin-binding protein 2 (PBP2) and interacting with bacterial cell wall synthesis[2,5].It exerts a bactericidal effects by disrupting cell wall synthesis.
The MICs for the Y. pestis strains with imipenem ranged from a low of 0.12 mg/liter to a high of 1.0 mg/liter,the highest is 0.5 mg/liter[7].Combination of relebactam with β-lactams led to >128- and 2-fold decreases in the MICs of amoxicillin and imipenem (from 8 to 4 mg/L). In vitro, M. abscessus was not killed by the imipenem/relebactam combination. In contrast, relebactam increased the intracellular activity of imipenem, leading to 88% killing[6]. A high dose of imipenem enhanced the interleukin (IL)-1β level [9] and natural killer (NK) cell activity[3].
Dose-dependent effect of subcutaneous administration of imipenem on the inflammatory responses in sepsis mice. A dose of 25 mg/kg imipenem resulted in better pathology, lower inflammatory mediators, and increased survival rate in sepsis mice[1].
References:
[1]: Khosrojerdi A, Soudi S, et,al. Imipenem alters systemic and liver inflammatory responses in CLP- induced sepsis mice in a dose-dependent manner. Int Immunopharmacol. 2021 Apr;93:107421. doi: 10.1016/j.intimp.2021.107421. Epub 2021 Feb 4. PMID: 33548581.
[2]: Acar JF, Goldstein FW, et,al. Activity of imipenem on aerobic bacteria. J Antimicrob Chemother. 1983 Dec;12 Suppl D:37-45. doi: 10.1093/jac/12.suppl_d.37. PMID: 6421793.
[3]: Ortega E, de Pablo MA, et,al. Modification of natural immunity in mice by imipenem/cilastatin. J Antibiot (Tokyo). 1997 Jun;50(6):502-8. doi: 10.7164/antibiotics.50.502. PMID: 9268007.
[4]: Ortega E, de Pablo MA, et,al. Modification of acquired immunity in mice by imipenem/cilastatin. J Antimicrob Chemother. 1999 Oct;44(4):561-4. doi: 10.1093/jac/44.4.561. PMID: 10588322.
[5]: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Imipenem-Cilastatin. 2017 Jan 17. PMID: 31644018.
[6]: Le Run E, Atze H, et,al.Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab β-lactamase on the in vitro and intracellular efficacy of imipenem. J Antimicrob Chemother. 2020 Feb 1;75(2):379-383. doi: 10.1093/jac/dkz433. PMID: 31637424.
[7]: Heine HS, Louie A, et,al. Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. Antimicrob Agents Chemother. 2014 Jun;58(6):3276-84. doi: 10.1128/AAC.02420-14. Epub 2014 Mar 31. PMID: 24687492; PMCID: PMC4068467.
亚胺培南是一种半合成的硫霉素。亚胺培南是一种广谱抗生素,通过与青霉素结合蛋白 2 (PBP2) 结合并与细菌细胞壁合成相互作用,对多种革兰氏阴性菌、革兰氏阳性菌、需氧菌和厌氧菌具有杀菌作用 [2,5].通过破坏细胞壁合成发挥杀菌作用。
鼠疫耶尔森菌株与亚胺培南的 MIC 范围从最低的 0.12 毫克/升到最高的 1.0 毫克/升,最高为 0.5 毫克/升[7]。组合relebactam 和 β-内酰胺导致 >;阿莫西林和亚胺培南的 MIC 分别降低 128 倍和 2 倍(从 8 mg/L 到 4 mg/L)。在体外,亚胺培南/relebactam 组合未杀死脓肿分枝杆菌。相比之下,relebactam 增加了亚胺培南的细胞内活性,导致 88% 的杀灭[6]。高剂量亚胺培南可增强白细胞介素 (IL)-1β 水平[9]和自然杀伤 (NK) 细胞活性[3]。
亚胺培南皮下给药对脓毒症小鼠炎症反应的剂量依赖性影响。 25 mg/kg 亚胺培南的剂量可改善脓毒症小鼠的病理学、降低炎症介质并提高存活率[1]。
















